Comments
Global Pharma companies in an effort to control R&D costs and increase efficiency are increasingly outsourcing their R&D projects. India with skilled workforce at a competitive cost stands to benefit from this trend. The Inflation Reduction Act should also help demand along with prevailing China +1 strategy. The R&D pipeline sees biologics/large molecules outpacing small molecules since FY18.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.